Evyatar SwissaNeuroscientistIsrael

Evyatar Swissa

I spent a decade learning how the brain breaks. Now I help build a platform to fix it.

Director of In-vivo Research, Modulight Bio · Research Associate, Weizmann Institute · PhD, Ben-Gurion University

Now

Turning a receptor into a dimmer switch

At Modulight Bio I direct in-vivo research on an optogenetic therapy. The platform uses optoGPCRs: light-activated G protein-coupled receptors delivered to the nerves that carry pain. Our workhorse is eOPN3, a rhodopsin borrowed from mosquitoes that recruits the Gi/o cascade and suppresses neurotransmitter release at the presynaptic terminal.

It does not force a neuron to fire, and it does not clamp it silent. It turns down what that terminal releases, and then lets it come back on its own. The first indication we are taking towards the clinic is trigeminal neuropathic pain, where the nerve is reachable enough for light to do the work.

The control in the corner is that mechanism, not a toggle. Hold it and the model goes quiet. Release it and the suppression decays on its own, the way a bistable opsin does.

Research

Why it breaks, what fixes it, and how a fix reaches a patient

One interface asked about three ways: the barrier between blood and brain, and the neurons whose excitability depends on it.

  • —

    Why it breaks

    Friedman lab · Ben-Gurion University

    Animal models of epilepsy and status epilepticus, following what happens in the weeks after the seizures stop. Blood-brain barrier pathology in the right place predicted which animals would become epileptic months later, accurately enough to serve as a biomarker. Treating early prevented the damage and the epilepsy alike.

  • —

    What it does when nothing is wrong

    PhD · Ben-Gurion University

    The same barrier, asked about in a brain that is not injured. Sustained sensory activity opens the microvessels of the cortex that receives it, and that opening travels with long-term synaptic plasticity. We saw it in rats, then in people.

  • — now

    Getting a fix to a patient

    Modulight Bio · Weizmann Institute

    An optogenetic therapy taken from a construct towards the clinic: delivery, implant design, chronic behavioural testing, and the preclinical evidence a regulator will read.

Path

The short version

  • —

    BSc, Chemistry

    Ben-Gurion University of the Negev
  • —

    Research assistant

    Experimental Neurosurgery · Ben-Gurion University
  • —

    MSc, Brain and Cognitive Sciences

    Ben-Gurion University of the Negev
  • —

    PhD, Brain and Cognitive Sciences

    Blood-Brain Barrier lab · Prof. Alon Friedman
  • — now

    Director of In-vivo Research

    Modulight Bio
  • — now

    Research Associate

    Weizmann Institute
Papers

Written down

For fun

The same habit, off the clock

Connect

Get in touch

Open to collaboration on neurovascular biology, optogenetic therapeutics, and behavioural pipelines that a regulator has to trust.

Hold to deliver light

Press and hold to deliver light to the model. Suppression persists after release and recovers on its own.